Nucleotide-based Therapeutics Market, Global Outlook and Forecast 2023-2029
Report ID
42797
Publisher
Market Monitor Global
Published Date
07-Dec
Delivery Format
PDF
No of Report Page
151
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details 
    This research report provides a comprehensive analysis of the Nucleotide-based Therapeutics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Nucleotide-based Therapeutics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Nucleotide-based Therapeutics, challenges faced by the industry, and potential opportunities for market players.
The global Nucleotide-based Therapeutics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Nucleotide-based Therapeutics market presents opportunities for various stakeholders, including Neuromuscular Diseases, hATTR. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Nucleotide-based Therapeutics market. Additionally, the growing consumer demand present avenues for market expansion.
The global Nucleotide-based Therapeutics market was valued at US$ 60320 million in 2022 and is projected to reach US$ 14820 million by 2029, at a CAGR of 3.9% during the forecast period.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
Key Features:
The research report on the Nucleotide-based Therapeutics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Nucleotide-based Therapeutics market.
Market Overview: The report provides a comprehensive overview of the Nucleotide-based Therapeutics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Antisense Oligonucleotides (ASO), siRNA), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Nucleotide-based Therapeutics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Nucleotide-based Therapeutics market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Nucleotide-based Therapeutics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
Market Segmentation and Forecast: The report segment the Nucleotide-based Therapeutics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Nucleotide-based Therapeutics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Nucleotide-based Therapeutics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Nucleotide-based Therapeutics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Nucleotide-based Therapeutics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Nucleotide-based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA
Market segment by Application
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other
Global Nucleotide-based Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Major players covered
    Sarepta Therapeutics
    Ionis Pharmaceuticals
    Alnylam
    Biogen
    Nippon Shinyaku
    Sobi
    Novartis
    BioNTech
    Pfizer
    Moderna Therapeutics
    Jazz Pharmaceuticals
    CureVac
    Regulus Therapeutics
    ProQR
    Secarna
    MiNA Therapeutics
    Sylentis
    Arrowhead
    Silence Therapeutics
    Dicerna
Outline of Major Chapters:
Chapter 1: Introduces the definition of Nucleotide-based Therapeutics, market overview.
Chapter 2: Global Nucleotide-based Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Nucleotide-based Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nucleotide-based Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
  • Table Of Content 
    1 Introduction to Research & Analysis Reports
    1.1 Nucleotide-based Therapeutics Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Nucleotide-based Therapeutics Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Nucleotide-based Therapeutics Overall Market Size
    2.1 Global Nucleotide-based Therapeutics Market Size: 2022 VS 2029
    2.2 Global Nucleotide-based Therapeutics Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Nucleotide-based Therapeutics Players in Global Market
    3.2 Top Global Nucleotide-based Therapeutics Companies Ranked by Revenue
    3.3 Global Nucleotide-based Therapeutics Revenue by Companies
    3.4 Top 3 and Top 5 Nucleotide-based Therapeutics Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Nucleotide-based Therapeutics Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Nucleotide-based Therapeutics Players in Global Market
        3.6.1 List of Global Tier 1 Nucleotide-based Therapeutics Companies
        3.6.2 List of Global Tier 2 and Tier 3 Nucleotide-based Therapeutics Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Nucleotide-based Therapeutics Market Size Markets, 2022 & 2029
        4.1.2 Antisense Oligonucleotides (ASO)
        4.1.3 siRNA
        4.1.4 mRNA
    4.2 By Type - Global Nucleotide-based Therapeutics Revenue & Forecasts
        4.2.1 By Type - Global Nucleotide-based Therapeutics Revenue, 2018-2023
        4.2.2 By Type - Global Nucleotide-based Therapeutics Revenue, 2024-2029
        4.2.3 By Type - Global Nucleotide-based Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Nucleotide-based Therapeutics Market Size, 2022 & 2029
        5.1.2 Neuromuscular Diseases
        5.1.3 hATTR
        5.1.4 COVID-19
        5.1.5 Other
    5.2 By Application - Global Nucleotide-based Therapeutics Revenue & Forecasts
        5.2.1 By Application - Global Nucleotide-based Therapeutics Revenue, 2018-2023
        5.2.2 By Application - Global Nucleotide-based Therapeutics Revenue, 2024-2029
        5.2.3 By Application - Global Nucleotide-based Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Nucleotide-based Therapeutics Market Size, 2022 & 2029
    6.2 By Region - Global Nucleotide-based Therapeutics Revenue & Forecasts
        6.2.1 By Region - Global Nucleotide-based Therapeutics Revenue, 2018-2023
        6.2.2 By Region - Global Nucleotide-based Therapeutics Revenue, 2024-2029
        6.2.3 By Region - Global Nucleotide-based Therapeutics Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Nucleotide-based Therapeutics Revenue, 2018-2029
        6.3.2 US Nucleotide-based Therapeutics Market Size, 2018-2029
        6.3.3 Canada Nucleotide-based Therapeutics Market Size, 2018-2029
        6.3.4 Mexico Nucleotide-based Therapeutics Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Nucleotide-based Therapeutics Revenue, 2018-2029
        6.4.2 Germany Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.3 France Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.4 U.K. Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.5 Italy Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.6 Russia Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.7 Nordic Countries Nucleotide-based Therapeutics Market Size, 2018-2029
        6.4.8 Benelux Nucleotide-based Therapeutics Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Nucleotide-based Therapeutics Revenue, 2018-2029
        6.5.2 China Nucleotide-based Therapeutics Market Size, 2018-2029
        6.5.3 Japan Nucleotide-based Therapeutics Market Size, 2018-2029
        6.5.4 South Korea Nucleotide-based Therapeutics Market Size, 2018-2029
        6.5.5 Southeast Asia Nucleotide-based Therapeutics Market Size, 2018-2029
        6.5.6 India Nucleotide-based Therapeutics Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Nucleotide-based Therapeutics Revenue, 2018-2029
        6.6.2 Brazil Nucleotide-based Therapeutics Market Size, 2018-2029
        6.6.3 Argentina Nucleotide-based Therapeutics Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Nucleotide-based Therapeutics Revenue, 2018-2029
        6.7.2 Turkey Nucleotide-based Therapeutics Market Size, 2018-2029
        6.7.3 Israel Nucleotide-based Therapeutics Market Size, 2018-2029
        6.7.4 Saudi Arabia Nucleotide-based Therapeutics Market Size, 2018-2029
        6.7.5 UAE Nucleotide-based Therapeutics Market Size, 2018-2029
7 Nucleotide-based Therapeutics Companies Profiles
    7.1 Sarepta Therapeutics
        7.1.1 Sarepta Therapeutics Company Summary
        7.1.2 Sarepta Therapeutics Business Overview
        7.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Major Product Offerings
        7.1.4 Sarepta Therapeutics Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.1.5 Sarepta Therapeutics Key News & Latest Developments
    7.2 Ionis Pharmaceuticals
        7.2.1 Ionis Pharmaceuticals Company Summary
        7.2.2 Ionis Pharmaceuticals Business Overview
        7.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Major Product Offerings
        7.2.4 Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.2.5 Ionis Pharmaceuticals Key News & Latest Developments
    7.3 Alnylam
        7.3.1 Alnylam Company Summary
        7.3.2 Alnylam Business Overview
        7.3.3 Alnylam Nucleotide-based Therapeutics Major Product Offerings
        7.3.4 Alnylam Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.3.5 Alnylam Key News & Latest Developments
    7.4 Biogen
        7.4.1 Biogen Company Summary
        7.4.2 Biogen Business Overview
        7.4.3 Biogen Nucleotide-based Therapeutics Major Product Offerings
        7.4.4 Biogen Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.4.5 Biogen Key News & Latest Developments
    7.5 Nippon Shinyaku
        7.5.1 Nippon Shinyaku Company Summary
        7.5.2 Nippon Shinyaku Business Overview
        7.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Major Product Offerings
        7.5.4 Nippon Shinyaku Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.5.5 Nippon Shinyaku Key News & Latest Developments
    7.6 Sobi
        7.6.1 Sobi Company Summary
        7.6.2 Sobi Business Overview
        7.6.3 Sobi Nucleotide-based Therapeutics Major Product Offerings
        7.6.4 Sobi Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.6.5 Sobi Key News & Latest Developments
    7.7 Novartis
        7.7.1 Novartis Company Summary
        7.7.2 Novartis Business Overview
        7.7.3 Novartis Nucleotide-based Therapeutics Major Product Offerings
        7.7.4 Novartis Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.7.5 Novartis Key News & Latest Developments
    7.8 BioNTech
        7.8.1 BioNTech Company Summary
        7.8.2 BioNTech Business Overview
        7.8.3 BioNTech Nucleotide-based Therapeutics Major Product Offerings
        7.8.4 BioNTech Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.8.5 BioNTech Key News & Latest Developments
    7.9 Pfizer
        7.9.1 Pfizer Company Summary
        7.9.2 Pfizer Business Overview
        7.9.3 Pfizer Nucleotide-based Therapeutics Major Product Offerings
        7.9.4 Pfizer Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.9.5 Pfizer Key News & Latest Developments
    7.10 Moderna Therapeutics
        7.10.1 Moderna Therapeutics Company Summary
        7.10.2 Moderna Therapeutics Business Overview
        7.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Major Product Offerings
        7.10.4 Moderna Therapeutics Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.10.5 Moderna Therapeutics Key News & Latest Developments
    7.11 Jazz Pharmaceuticals
        7.11.1 Jazz Pharmaceuticals Company Summary
        7.11.2 Jazz Pharmaceuticals Business Overview
        7.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Major Product Offerings
        7.11.4 Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.11.5 Jazz Pharmaceuticals Key News & Latest Developments
    7.12 CureVac
        7.12.1 CureVac Company Summary
        7.12.2 CureVac Business Overview
        7.12.3 CureVac Nucleotide-based Therapeutics Major Product Offerings
        7.12.4 CureVac Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.12.5 CureVac Key News & Latest Developments
    7.13 Regulus Therapeutics
        7.13.1 Regulus Therapeutics Company Summary
        7.13.2 Regulus Therapeutics Business Overview
        7.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Major Product Offerings
        7.13.4 Regulus Therapeutics Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.13.5 Regulus Therapeutics Key News & Latest Developments
    7.14 ProQR
        7.14.1 ProQR Company Summary
        7.14.2 ProQR Business Overview
        7.14.3 ProQR Nucleotide-based Therapeutics Major Product Offerings
        7.14.4 ProQR Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.14.5 ProQR Key News & Latest Developments
    7.15 Secarna
        7.15.1 Secarna Company Summary
        7.15.2 Secarna Business Overview
        7.15.3 Secarna Nucleotide-based Therapeutics Major Product Offerings
        7.15.4 Secarna Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.15.5 Secarna Key News & Latest Developments
    7.16 MiNA Therapeutics
        7.16.1 MiNA Therapeutics Company Summary
        7.16.2 MiNA Therapeutics Business Overview
        7.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Major Product Offerings
        7.16.4 MiNA Therapeutics Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.16.5 MiNA Therapeutics Key News & Latest Developments
    7.17 Sylentis
        7.17.1 Sylentis Company Summary
        7.17.2 Sylentis Business Overview
        7.17.3 Sylentis Nucleotide-based Therapeutics Major Product Offerings
        7.17.4 Sylentis Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.17.5 Sylentis Key News & Latest Developments
    7.18 Arrowhead
        7.18.1 Arrowhead Company Summary
        7.18.2 Arrowhead Business Overview
        7.18.3 Arrowhead Nucleotide-based Therapeutics Major Product Offerings
        7.18.4 Arrowhead Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.18.5 Arrowhead Key News & Latest Developments
    7.19 Silence Therapeutics
        7.19.1 Silence Therapeutics Company Summary
        7.19.2 Silence Therapeutics Business Overview
        7.19.3 Silence Therapeutics Nucleotide-based Therapeutics Major Product Offerings
        7.19.4 Silence Therapeutics Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.19.5 Silence Therapeutics Key News & Latest Developments
    7.20 Dicerna
        7.20.1 Dicerna Company Summary
        7.20.2 Dicerna Business Overview
        7.20.3 Dicerna Nucleotide-based Therapeutics Major Product Offerings
        7.20.4 Dicerna Nucleotide-based Therapeutics Revenue in Global Market (2018-2023)
        7.20.5 Dicerna Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
Email: inquiry@wiredrelease.com
SHORT NAVIGATION
connect with us